Sponsor hub

University Health Network, Toronto clinical trial failures

Review 47 stopped clinical trials from University Health Network, Toronto, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 0 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials47
Likely biological signals0
Shown below47

Dominant stop reasons

OPERATIONAL
33
OTHER/UNKNOWN
14

Notable sponsors

University Health Network, Toronto
47

Related phases

Phase II
24
Phase I
11
Unknown
5
Phase III
3
Phase IV
3

Crawlable stopped-trial records

Open Explore

Showing up to 47 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT06191250: --SuPERIOR Trial--

Phase II Non-Small Cell Lung Cancer (NSCLC) trial by University Health Network, Toronto. Stop reason: OTHER/UNKNOWN.

Study Terminated Prior to trial activation, due to changes in SOC of the treatment

NCT06710197: IL-1 Inhibition in Early TNBC

Phase II Early Stage Triple Negative ER Low Breast Cancer trial by University Health Network, Toronto. Stop reason: OPERATIONAL.

Terminated with sponsor-investigator agreement due to extended period without enrollment and the absence of foreseeable participant accrual. No participants were enrolled.

NCT04262388: A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

Phase II Pancreatic Ductal Adenocarcinoma trial by University Health Network, Toronto. Stop reason: OTHER/UNKNOWN.

Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet.